Bard v. Gore: Joint Inventors or Just One?

In view of the recent petition for cert. filed by W. L. Gore, asking the Supreme Court to review the standards for joint inventorship, the February panel decision in Bard Peripheral Vascular, Inc. v. W. L. Gore & Assoc., Inc., 670 F.3d 1171 (Fed. Cir. 2012) just got a lot more interesting. The Fed. Cir. affirmed the panel decision en banc in June, (682 F.3d 1003), but did not disturb the panel’s 3/2 finding that the claimed PTFE (Gore-Tex®) vascular grafts were a sole, not a joint invention. What is unusual about this decision is that the “maker”, Cooper – an employee of Gore – was found not to be an inventor, while the “tester” – one Goldfarb, a surgeon at the Arizona Heart Institute, was found to be the sole inventor. In other words, while acknowledging that Cooper actually had the invention in hand and sent it to Goldfarb for testing, Cooper was found to know so little about the tubes he sent, that Goldfarb’s discovery of the critical claim element not only was sufficient to make him a co-inventor, but his work did not “inure” to the benefit of Cooper to the extent that Cooper should be properly named as a co-inventor.

The grafts comprised expanded, porous PTFE having a microstructure consisting of nodes interconnected by fibrils, which permits tissue ingrowth, where an average distance between nodes is not less that about 6 microns. Now things get complicated.

Continue reading

Posted in Inventorship | Tagged , , , , , , | Leave a comment

ACI Biotech Conference in Boston – What’s New?

A lot of the speakers will have big changes in patent law and watershed case law to tackle at the American Conference Institute’s 14th Advanced Forum on Biotech Patents in Boston, Nov. 28-29, 2012. I will be speaking with Kevin Noonan on the use of the inequitable conduct defense post-Therasense and on the use of the AIA and reissue to address “fraud” issues and strengthen patents pre-litigation.

Other topics include updates and practical advice on rebutting obviousness rejections and the tensions that can create with the tenants of the “new and improved” written description requirement of Ariad (John Ivanicki, Alexander Wilson, Matthew Beaudet , Amy Hamilton and Filko Prugo). The Keynote address will be delivered by Terry Rea, Deputy Director of the PTO, with other PTO insights coming from George Elliott, the Director of 1600 and Esther Kepplinger, former Assistance Director of Examination Policy and Bob Stoll, former Commissioner of Patents.  Other topics include Biosimilars, 101 issues and Akami/McKesson. So this is not just another AIA Conference. Y’all come!

ACI Biotech Conference

Posted in Conferences and Classes | Tagged , , , , , , , , | Leave a comment

Re-Election of Obama Keeps Patent Law and Policy on Track

At least Director Kappos does not have to clean out his desk. The re-election of President Obama gives him another four years of job security – if he and his hard-working staff don’t burn out first. No matter what you think of the AIA, Director Kappos has done a remarkable job of proposing implementing regulations for its many new procedures. Apart from issuing rules by the bushel, he has been “tasked” with opening three new satellite offices. He has begun to develop guidance in non-AIA areas such as patenting diagnostic assays post-Prometheus. The defeat of President Obama might well have caused a return to the Rogan years of a “know nothing” [about patent law] Commissioner.

A President Romney surely would have supported repeal of “Obamacare”. No matter what you think of the more controversial parts of the law, it also contains the outline of procedures to approve generic biologicals, a way to cut healthcare costs that is long overdue. At least the players can continue to move forward, and not be put into limbo or returned to the starting line to run a race with new rules.

Continue reading

Posted in Govt Policy/PTO Policy | Tagged , , , , , , , | Leave a comment

Voter Verified Decision Elaborates on Internet Publication

Yesterday a panel of Judges (Lourie, Reyna and Wallach) in Voter Verified, Inc. v. Premier Election Solutions, Appeal nos. 2011-1559, 2012-1016 (Fed. Cir. November 5, 2012) expanded on the Fed. Cir.’s earlier decision In re Lister, 583 F.3d 1307 (Fed. Cir. 2009)(archived under “Prior Art”), which in turn cited In re Klopfenstein, 380 F.3d 1345 (Fed. Cir. 2004), to affirm a district court’s holding that a patent on “a self-verifying voting system” was obvious in view of an article (the “Benson article”) that had been posted on the “Risks Digest Website” well prior to the 102(b) bar date.

Noting that the “key inquiry is whether the reference was made ‘sufficiently available to the public interested in the art’ before the critical date”, Klopfenstein was quoted as establishing that “Whether a reference is publicly available is determined on a case-by-case basis based on the facts and circumstances surrounding the reference’s disclosure to member of the public.”

Continue reading

Posted in Prior Art | Tagged , , , , , | 1 Comment